PT  - JOURNAL ARTICLE
AU  - Mitchell, Henry
AU  - Siegel, Ava
AU  - Tien, Lauren
AU  - Stultz, Mallory
AU  - maclean, charles
AU  - Zweber, Cole
AU  - Yalovitser, Josephine
AU  - levine, jonah
TI  - Vermont Stakeholder Views Regarding Psychedelics in 2023
AID  - 10.1370/afm.22.s1.5477
DP  - 2023 Nov 01
TA  - The Annals of Family Medicine
PG  - 5477
VI  - 21
IP  - Supplement 3
4099  - http://www.annfammed.org/content/21/Supplement_3/5477.short
4100  - http://www.annfammed.org/content/21/Supplement_3/5477.full
SO  - Ann Fam Med2023 Nov 01; 21
AB  - Context: While Indigenous communities have used psychedelics for millennia, scientific research on these substances is limited. Following a rise in recreational use of psychedelics during the Counterculture Movement of the 1960s, many psychedelics were restricted by the Drug Enforcement Agency. The past fifteen years has seen an increase in research regarding the therapeutic potential of psychedelics, especially for mental health indications. Many states and local jurisdictions are easing restrictions on access to some of these substances for medical or more widespread use.Objective: To assess stakeholder opinions regarding psychedelics in VermontAnalysis: Following a literature review, an interview guide was developed to explore current attitudes on the state of psychedelic policy, training, and treatment practices. Using thematic analysis, interview transcripts were coded and themes developed via group consensus.Setting: Community stakeholders in VermontPopulation: Convenience sample of 16 healthcare providers, public health officials, legislators, investors, advocates, and law enforcement officersInstrument: Semi-structured interviewOutcome Measures: Attitudes towards psychedelics, awareness of psychedelic use, and potential concernsResults: Three main themes emerged: On the ENVIRONMENT, there was cautious optimism among stakeholders that psychedelic therapies may have a big impact on the treatment of mental health and an awareness that many jurisdictions are increasing access. The growing mental health crisis in the US was seen as a driver of need for new approaches. IMPLEMETATION was seen as critical, including 1) medical vs personal use model of adoption, 2) the importance of the the user’s mindset and the setting of use, and 3) the regulations around education, and access. Participants also had CONCERNS. On safety, the substances are seen to be non-toxic but further research is needed before widespread adoption is recommended. On accessibility, participants were concerned about costs and equity in access. Finally, participants were concerned about overzealousness and widespread use preceding knowledge about the risks and benefits.Conclusions: Psychedelics are undergoing a cultural and scientific revival, driven by evolving legislation and renewed academic interest. The growing body of research indicates promise in addressing intractable mental health disorders, Vermont stakeholders are cautious about hasty implementation and overzealousness.